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Background: Atrial fibrillation (AF) systematic screening studies have not shown a clear
usefulness in stroke prevention, as AF might present as paroxysmal and asymptomatic.
This study aims to determine the usefulness of some blood-biomarkers to identify
paroxysmal atrial fibrillation in the context of a screening programme.
Methods: A total of 100 subjects aged 65–75 years with hypertension and diabetes
were randomly selected. AF was assessed by conventional electrocardiogram (ECG)
and 4 weeks monitoring with a wearable Holter device (NuuboTM). N-terminal pro
B-type natriuretic peptide (NT-proBNP), apolipoprotein CIII (ApoC-III), von Willebrand
factor (vWF), ADAMTS13, urokinase plasminogen activator surface receptor (uPAR), and
urokinase plasminogen activator (uPA) were determined in serum/plasma samples and
the levels were compared depending on AF presence and mode of detection.
Results: The AF prevalence in the studied population was found to be 20%. In
seven subjects, AF was only detected after 1 month of Holter monitoring (hAF group).
NT-proBNP levels were higher in subjects with AF compared with subjects with no
AF (p < 0.0001), even when only taking into account the hAF group (p = 0.031). No
significant differences were found in the other biomarkers. The NT-proBNP >95 pg/ml
cut-off showed high sensitivity and specificity to detect AF (95%, 66.2%) or hAF (85.72%,
66.2%) and was found to be an independent predictor of AF and hAF in a logistic
regression analysis. NT-proBNP correlated with AF burden (r = 0.597, p = 0.024).
Conclusion: NT-proBNPwas elevated in AF cases not identified by ECG; thus, it may be
used as a screening biomarker in asymptomatic high-risk populations, with a promising
cut-off point of 95 pg/ml that requires further validation.
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INTRODUCTION
Atrial fibrillation (AF) is one of the fastest-growing
cardiovascular epidemics of the twenty-first century (1).
This heart rhythm disorder multiplies by five the risk of ischemic
stroke (2), and its prevalence in the population over 60 years has
been quantified at 10.9% (3). Anticoagulation may reduce stroke
risk in AF individuals by ∼60% (4), but unfortunately, given
its paroxysmal and asymptomatic nature at earlier stages, AF
is often undiagnosed and/or undertreated when stroke occurs.
In a previous study, the absolute prevalence of undiagnosed AF
in individuals over 60 years was 3.4%, representing up to 31%
of the overall AF prevalence in our area (5, 6). International
collaborations (7, 8) recommend opportunistic screening for
AF in patients >65 years as a strategy to reduce stroke and
death, but systematic screening programmes have failed to
show a clear benefit and those strategies are lacking in high-risk
populations (9–11).
Blood biomarkers might represent an alternative tool for AF
screening, because some of them might have elevated circulating
levels after AF paroxysms, a kind of “biological memory” offering
a temporal advantage over electrical detection of the paroxysm
itself. N-terminal pro B-type natriuretic peptide (NT-proBNP)
has been found to be elevated in cardioembolic (CE) stroke
(12) and to be associated with AF (13–16). Von Willebrand
factor (vWF) was found to be elevated in non-valvular AF (17)
and, together with apolipoprotein CIII (ApoC-III), was found
to be predictor of stroke CE etiology [unpublished results from
the Stroke-Chip study (18)]. ADAMTS-13 is the key regulator
of vWF, and it has been associated with AF recurrence after
cardioversion (19). Urokinase plasminogen activator surface
receptor (uPAR) has been associated with AF prevalence (20)
while its ligand, urokinase plasminogen activator (uPA), has not
been studied in AF patients.
This study aims to determine the usefulness of the
aforementioned biomarkers to identify AF individuals in the
context of a screening programme, especially in cases of
paroxysmal AF that would not be detected using a regular 12-
lead ECG.
MATERIALS AND METHODS
Patients and Protocol
AFRICAT (Atrial Fibrillation Research in CATalonia;
NCT03188484) is an observational, multicenter, population-
based study with the aim of developing a screening programme
to detect new cases of AF in high-risk individuals in primary
care centers. In Phase I of the project, 100 subjects aged 65–75
with hypertension and diabetes were selected from primary care
registers (e-cap), which include the clinical records from most
Catalonia inhabitants between January 2016 and December 2017.
In two different health service areas, Servei d’Atenció Primària
(SAP) Muntanya and SAP Terres de l’Ebre, patients fulfilling the
inclusion criteria were identified in primary care centers from
each catchment [Centre d’Atenció Primària (CAP) Sant Rafael
and CAP Trinitat Vella in SAP Muntanya; Equip d’Atenció
Primària (EAP) Tortosa Est and EAP Tortosa Oest in SAP Terres
de l’Ebre]. Physicians from these primary care centers were
informed about the study protocol, and patients were invited by
them to participate in the study until 50 patients were recruited
in each catchment. Participants were ambulatory patients in a
basal situation, meaning they were contacted at home to arrange
a visit in their primary care center specifically for the study.
During the appointments, patients received a comprehensive
assessment consisting of clinical characteristics (demographic
factors, vascular risk factors, medications, comorbidities, and
vitals), electrographic assessment and a blood sample collection.
Comorbid conditions were defined using standard outpatient
and inpatient ICD-10 codes by electronic data capture, including
pharmacy records, laboratory data, and emergency room
and hospitalization diagnoses across all primary care centers
and hospitals.
Individuals with chronic inflammatory diseases, cancer or
dementia were excluded. AF was assessed by conventional
electrocardiogram (ECG). Moreover, patients were monitored
for 4 weeks with a wearable Holter device (NuuboTM) as
described previously (21). The Holter device was composed of
a sensor that captured the electrocardiographic signal by non-
invasive textile electrodes and a recorder of the signal that stored
the information for subsequent detailed analysis. Participants
were instructed by local trained researchers to wear the Holter
for 23 h and recharge it for 1 h daily. After 4 weeks, individuals
brought the Holter to their primary care center, and data were
collected. Holter records, anonymized and encrypted, were sent
together with the ECG for blinded reading to the Rhythm
Disorders Unit at the Cardiology Department of Hospital Virgen
del Rocio in Seville, to verify AF episodes. AF was defined
following AHA guidelines as irregular R-R intervals without a
P wave signal, lasting for more than 60 s (22). Individuals with
previous AFwere not excluded at this step, butHoltermonitoring
was optional in this subgroup.
Patients were classified and compared in five groups defined
by past medical history (PMH) for AF, ECG findings and
Holter AF detection as follows: no AF, PMH-ECG-Holter+
[Holter-detected AF (hAF)], PMH-ECG+, PMH+ECG-, and
PMH+ECG+. Specific comparisons were done between the hAF
and no AF groups.
The AFRICAT study protocol was approved by the clinical
research ethics committees of IDIAP Jordi Gol (P15/047) and
Hospital Universitari Vall d’Hebron [PR (AG) 133-2015]. All
participants signed informed consent before inclusion. The
study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki.
Biomarker Measurement
Blood was collected into EDTA and serum tubes at the
time of inclusion. After centrifugation at 1,500 g and 4◦C for
15min, plasma and serum aliquots were frozen at −80◦C until
biomarker determination.
Plasma NT-proBNP levels were determined by automated
immunoassay in a COBAS c8000 (Roche Diagnostics); serum
ApoC-III, plasma uPAR and plasma uPA by ELISA (Abnova,
R&D Systems, and Cloud-Clone); and plasma vWF and
ADAMTS13 by a magnetic Luminex R© assay (R&D Systems).
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All assays were performed blinded to clinical information and
according to the manufacturer’s instructions. All samples were
tested in duplicate and inter-assay variation was determined by a
commercial control (Human Serum, male AB, USA origin from
clotted, SIGMA, ref number H16914; Human plasma K2 EDTA,
Innovative Research, ref number IPLA-N) tested in duplicate
in each plate. When inter-assay variation was >20% biomarker
levels were standardized using the Z-score.
Statistical Analysis
Statistical analysis was conducted with SPSS version 20. Graphs
were elaborated with GraphPad Prism 6. Data are expressed
as number (%) for categorical variables and as mean ± SD or
median (interquartile range) for continuous variables, depending
on the data distribution. For univariate analysis, the Mann–
Whitney U-test or Student’s t-test was used for continuous
variables, and the χ2 test was used for categorical variables.
ANOVA or the Kruskal–Wallis test was used to compare
>2 variables depending on variable distribution. Receiver
operator characteristic (ROC) curves were configured to calculate
sensitivity, specificity, and cut-off values. The Spearman test was
used for correlations. Comparisons were first performed between
AF patients and no AF patients and second between hAF and
no AF patients (excluding other subtypes of AF). Binary logistic
regression analysis was performed including variables associated
with AF or hAF in univariate analysis.
RESULTS
Patient Characteristics and AF Detection
Clinical characteristics of the cohort can be found in Table 1.
Coronary heart disease (p = 0.008), heart failure (p = 0.007),
valvular diseases (p = 0.024), and use of anticoagulants
(p < 0.0001) were more common in AF individuals. Of
the 9 anticoagulated individuals, only one was anticoagulated
for reasons other than AF (ischemic cardiopathy and deep
venous thrombosis). The CHA2DS2-VASc score was higher in
AF individuals (p = 0.035). Coronary heart disease ischemia
was more common in hAF individuals compared to no AF
(p = 0.032). No cases of heart failure, valvular disease or
anticoagulation were present in this subgroup.
Of the included 100 individuals, 96 were monitored with
ECG Holter. All patients with negative ECG were monitored.
Median monitoring time was 457 h. Six cutaneous adverse events
related to wearing the Holter were noted; these consisted of a
rash that normally disappeared with topical steroids. However,
in two subjects, these adverse events prevented the monitoring
being continued.
Of the 100 selected subjects, AF was present in 20 (11 newly
detected within the present study) classified as follows: 7 PMH-
ECG-Holter+ (hAF), 4 PMH-ECG+, 2 PMH+ECG-, and 7
PMH+ECG+ (Figure 1).
In 14 individuals (11 newly detected and 3 PMH+ECG+
were monitored), AF was detected during Holter monitoring and
AF burden was calculated. AF burden was defined as minutes
being in AF divided by the total minutes of readable records
and is expressed as a percentage. The median AF burden was
10.35% (1.00–56.50).
Biomarker Analysis
NT-proBNP, ApoC-III, sUPAR, vWF, and ADAMTS13 inter- and
intra-assay variation was acceptable (coefficient of variation<20);
hence, all the samples were included in the analysis. uPA levels
were standardized because the inter-assay variation was higher
than 20%, and 9 samples were eliminated from statistical analysis
TABLE 1 | Clinical characteristics of the cohort and comparison according to atrial fibrillation diagnosis.
All patients (100) AF (20) No AF (80) hAF (7) P-valuea P-valueb
Age 70 (68–73) 69 (66–71.5) 70 (68–73) 70 (65–72) 0.273 0.655
Sex (% female) 33 (33) 7 (35) 26 (32.5) 3 (42.9) 0.832 0.682
Tobacco 20 (20) 4 (20) 16 (20.3) 1 (14.3) 1.000 1.000
Alcohol 11 (11) 1 (5) 10 (12.5) 0 (0) 0.456 1.000
Dyslipidaemia 81 (81) 16 (80) 65 (81.3) 5 (71.4) 1.000 0.619
Coronary heart disease 18 (18) 8 (40) 10 (12.5) 3 (42.9) 0.008* 0.032*
Heart failure 3 (3) 3 (15) 0 (0) 0 (0) 0.007* 1.000
Valvular disease 4 (4) 3 (15) 1 (1.3) 0 (0) 0.024* 0.767
Previous stroke 6 (6) 2 (10) 4 (5) 0 (0) 0.597 1.000
Anticoagulation 9 (9) 8 (40) 1 (1.3) 0 (0) 0.000* 0.920
Antiplatelets 50 (50) 7 (35) 43 (53.8) 3 (42.9) 0.134 0.702
Familiar history FA 5 (5) 2 (10) 3 (3.9) 0 (0) 0.273 1.000
SBP, mm Hg 143.50 (134–153) 140.5 (127.5–162.5) 144 (134–151.75) 140 (124–168) 0.973 0.773
DBP, mm Hg 78.95 ± 10.09 80.95 ± 10.85 78.45 ± 9.90 79.14 ± 6.66 0.332 0.857
Heart rate 77.94 ± 15.70 77.25 ± 16.94 78.11 ± 15.48 73 ± 22.14 0.724 0.421
CHA2DS2-VASc 4 (3–4) 4 (3–4) 4 (3–5) 4 (3–5) 0.035* 0.284
aP-value comparison AF vs. no AF.
bP-value comparison hAF vs no AF.
*P < 0.05. AF, atrial fibrillation; DBP, diastolic blood pressure; hAF, Holter-detected atrial fibrillation; SBP, systolic blood pressure.
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FIGURE 1 | Subject classification. Individuals were classified depending on AF presence and subgroups were made depending on AF detection with different
methods and previous medical history.
TABLE 2 | Biomarker levels and comparisons between different groups.
AF (20) No AF (80) hAF (7) P-valuea P-valueb
NT-proBNP (pg/ml) 643.65
(155.72–1339.25)
64.28 (37.08–133.10) 128.30
(97.69–191.8)
<0.0001* 0.03*
ApoC-III (ng/ml) 107,594
(92,501–129262.06)
104,450 (766,64–130,393) 105,352
(91,956–132,268)
0.496 0.574
ADAMTS13 (ng/ml) 1131.24 ± 471.419 1221.41 ± 459.80 1271.68 ± 561.01 0.437 0.786
vWF (ng/ml) 0.139 ± 0.052 0.139 ± 0.706 0.146 ± 0.060 0.987 0.802
uPA (std)c 2.01 (1.41–2.39) 1.60 (1.38–2.35) 1.68 (1.29–2.35) 0.720 0.868
uPAR (pg/ml) 2220.80
(557.74–2810.52)
2267.54 (1518.33–2763.05) 2246.12
(1926.03–259.23)
0.689 0.918
aP-value comparison AF vs. no AF.
bP-value comparison hAF vs. no AF.
cNinety-one individuals included in the uPA analysis (73 no AF and 18 AF, of whom 6 were hAF).
*P < 0.05. AF, atrial fibrillation; ApoC-III, Apolipoprotein C-III; hAF, Holter-detected group; NT-proBNP, N-terminal pro B-type natriuretic peptide; vWF, von Willebrand factor; uPA,
urokinase plasminogen activator; uPAR, urokinase plasminogen activator surface receptor.
because their duplicates showed CV > 20%. Median levels and
comparisons are shown in Table 2.
AF vs. No AF
NT-proBNP was significantly higher in individuals with AF
compared with no AF [643.65 pg/ml (IQR 155.72–1339.25)
vs. 64.28 pg/ml (IQR 37.08–133.10), p < 0.0001; Figure 2A],
while the remaining biomarkers were not different between
the two groups (Supplementary Figures 1, 2). The NT-proBNP
distribution across the different subgroups is shown in Figure 2B.
In addition, AF burden was correlated with NT-proBNP (r =
0.597, p = 0.024; Figure 2D). The discriminating ability (area
under the ROC curve) of NT-proBNPwas 0.900 (95%CI, 0.8274–
0.9726, p < 0.0001) to detect any AF (Figure 3A). The cut-off
point of NT-proBNP of>95 pg/ml showed 95% sensitivity, 66.2%
specificity, 41.3% positive predictive value (PPV), and 98.1%
negative predictive value (NPV) to detect any AF (Figure 3C).
Anticoagulants (OR = 18.90; 95% CI, 2.10–169.83; p = 0.09)
and NT-proBNP>95 pg/ml (OR= 22.42; 95% CI, 2.74–183.15; p
= 0.04) were the only independent predictors of AF in the logistic
regression analysis performed in the whole cohort. CHA2DS2-
VASc was an independent AF predictor when considered alone
in the regression analysis (OR = 2.29; 95% CI 1.16–4.44; p =
0.017). However, after the addition of NT-proBNP>95 pg/ml,
CHA2DS2-VASc was not significant in the model.
Alternatively, the cut-off point of NT-proBNP of >125 pg/ml,
which is recommended for heart failure diagnosis in the non-
acute setting, showed 85% sensitivity and 73.8% specificity, 44.7%
PPV and 95.2% NPV. NT-proBNP>125 pg/ml was also an
independent predictor of AF (OR = 8.85; 95% CI, 2.17–35.95;
p= 0.017).
Sensitivity analysis was performed while excluding the patient
who was anticoagulated for reasons other than AF, and the results
were similar.
hAF vs. No AF
NT-proBNP levels were different between no AF and hAF [64.28
pg/ml (IQR 37.08–133.10) vs. 128.3 pg/ml (IQR 97.69–191.3),
p = 0.031; Figure 2C] while other biomarkers did not show
differences (Supplementary Figures 1, 2). Patients without AF
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FIGURE 2 | Plasma NT-proBNP level distribution. (A) Boxplot distribution between AF and no AF. (B) Boxplot distribution between different groups depending on past
medical history (PMH) for AF, ECG findings, and Holter monitoring. (C) Boxplot distribution between Holter-detected AF (hAF) and no AF. (D) Correlation between
NT-proBNP levels and AF burden. *P < 0.05.
and with a Holter monitoring time below the median (457 h)
were removed and all aforementioned comparisons were tested
again, with similar results (data not shown). The discriminating
ability (area under the ROC curve) of NT-proBNP was 0.7464
(95% CI 0.6087–0.8841, p = 0.031) to detect hAF (Figure 3B).
The cut-off point of NT-proBNP of >95 pg/ml showed 85.7
% sensitivity, 66.2% specificity, 18.2% PPV, and 98.1% NPV to
detect hAF (Figure 3C).
The logistic regression analysis performed on this subgroup
confirmed that NT-proBNP ≥95 pg/ml was an independent
predictor of Holter-detected atrial fibrillation (OR, 11.778;
95% CI, 1.35–102.85; p = 0.026). No clinical variable was an
independent predictor of AF detection.
Alternatively, the cut-off point of NT-proBNP of >125
pg/ml showed 55.1% sensitivity, 73.8% specificity, 16% PPV, and
95.2% NPV. NT-proBNP >125 pg/ml also was an independent
predictor of AF (OR = 8.85; 95% CI 2.17–35.95; p = 0.017). NT-
proBNP >125 pg/ml was not an independent predictor of hAF.
DISCUSSION
The prevalence of AF in our population was 20%, of which
55% were newly detected AF individuals. This prevalence is
higher than reported in previous screening studies (from 2.3 to
12.3%) (10, 11). Most such studies have only used ECG or pulse
devices instead of long-term monitoring, so they have missed
cases of paroxysmal AF. Moreover, we used a targeted screening
approach, focussing on a high-risk population with advanced
age and other conditions related to AF, such as hypertension
and diabetes, who should present a higher AF prevalence (23).
Longer monitoring in a high-risk population might therefore be
a good strategy to further explore in larger cohorts. Other studies
using long-term monitoring with insertable cardiac devices or
pacemakers in patients without prior history of AF have also
shown a higher prevalence of AF (24). In fact, in the recent
REVEAL AF trial, detection rates of AF rose with the monitoring
time (25). Moreover, in patients with cryptogenic stroke, long-
term monitoring was found to be associated with higher rates of
AF detection, with a significant impact in secondary prevention
(26). However, although it could become the gold standard
for AF detection, long-term monitoring devices are expensive
and unsuitable for application in primary care. In that sense,
biomarkers might be used as cost-effective alternatives for AF
systematic screening.
The present study suggests that NT-proBNP might be used
as a screening biomarker to detect even paroxysmal AF in
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FIGURE 3 | NT-proBNP discrimination power. (A) ROC curve: ability to discriminate between AF and no AF. (B) ROC curve, ability to discriminate between
Holter-detected AF and no AF. The cut-off with the best specificity and sensitivity to detect hAF is marked with a circle in the two curves (95 pg/ml), as it is the cut-off
value that was used to calculate sensitivity, specificity and predictive values. (C) Discrimination power of the NT-proBNP cut-off value of 95 pg/ml. All AF individuals
had NT-proBNP plasma levels below the previous cut-off (except for a patient with paroxysmal AF), and the majority of no AF patients had values above the cut-off.
asymptomatic, high-risk individuals. The focus of the present
study was to assess the predictive ability of NT-proBNP and
other biomarkers to diagnose paroxysmal atrial fibrillation and
be used as the first step of a screening workflow. In fact, the
best screening biomarker in this context would be able to detect
those cases impossible to notice with other available tools, such
opportunistic ECG or hand-held ECG devices. It should be
mentioned that paroxysmal AF (pAF) patients also can have
increased risk of stroke (27, 28). Moreover, pAF may progress to
permanent AF within a year in almost 20% of cases in the aging
population (29, 30).
Previous studies have suggested NT-proBNP as a
screening tool (14–16), but a limited length of monitoring
might have misclassified some cases of paroxysmal
atrial fibrillation. Our study overcame this limitation by
recording patient’s heart rhythm continuously for 30 days
using a Holter monitor, allowing us to detect more AF
cases. This is to our knowledge the longest period over
which asymptomatic individuals have been monitored
to detect atrial fibrillation in a biomarker study, if we
exclude studies using pacemakers (13). The limitation of
pacemakers is that their use is restricted to very specific
populations with cardiac diseases that could affect some
biomarker levels.
In the pilot study of Seegers et al. (14), in addition to a
limited 7-day Holter ECG for the evaluation of paroxysmal AF,
patients were preselected as those with lowest and highest NT-
proBNP quartiles, overestimating the discriminatory value of
the biomarker. In our study, inclusion was performed before
any biomarker determination, and 4-week Holter monitoring
was used as the gold standard to assess the usefulness of
blood-based biomarkers in AF screening. Although individuals
with AF detected by other methods were not excluded from
the whole study, to increase the statistical power, specific
comparisons were performed while excluding these patients and
only taking into account AF cases detected with long-term
monitoring, i.e., cases with neither previous AF history nor
detection during electrocardiographic assessment. Even though
few patients were part of this group, specific comparisons
showed the usefulness of NT-proBNP to identify those patients
outside AF paroxysms. After validating those results with
a larger cohort, NT-proBNP could be implemented as part
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of a screening programme to indicate long-term monitoring
in patients with a risk biological profile. Such a protocol
would identify patients at risk of AF who would benefit from
anticoagulation, thereby improving primary stroke prevention
by preventing cardioembolic stroke, which is associated with
the poorest disability and mortality rates among stroke
etiologies (31).
Additionally, we proposed for the first time a specific cut-off
point for atrial fibrillation screening. Seegers et al. (14) suggested
that NT-proBNP could be used for stroke prevention after finding
increased values in AF individuals, without indicating any cut-
off. Svenberg et al. (15) and Ghazal et al. (16) proposed a cut-off
point of NT-proBNP>125 pg/ml, which is the recommended for
heart failure in the non-acute setting (32). Here, NT-proBNP>95
pg/ml reached high sensitivity (95%) even to detect paroxysmal
AF individuals (85.7%). In fact, in our cohort, this cut-off point
only misclassified one paroxysmal AF individual. Although the
NT-proBNP biomarker is not specific for AF and might be
elevated in other cardiac diseases and renal dysfunction (33),
a high sensitivity is more useful than specificity for screening
purposes. NT-proBNP might be rapid and easy to use to identify
all patients who need follow-up Holter monitoring since it is
already widely employed as a point-of-care analysis tool for
heart failure.
Although it might be suspected that elevated NT-proBNP
levels were due to a higher burden of heart failure and other
cardiovascular diseases in the atrial fibrillation subjects of our
cohort, in the hAF group, there were few individuals with
known comorbidities that could affect NT-proBNP levels. In fact,
in this group, there were no cases of heart failure, and there
were only differences in coronary heart disease when compared
to no AF individuals. In addition, the study was carried out
at the outpatient clinic, and therefore, no patient was in a
situation of acute decompensated heart failure. This, combined
with multivariate analysis, confirmed the independent value of
NT-proBNP in diagnosing paroxysmal atrial fibrillation.
ApoC-III, vWF, ADAMTS13, uPAR, and uPA were not
elevated in AF individuals in the present study. Although
associated with cardioembolic stroke or AF recurrence, these
biomarkers might not be useful in the context of AF
screening. However, it would be interesting to perform further
discovery studies to find new biomarkers that might be used
in combination with NT-proBNP, increasing its specificity
and sensitivity.
Interestingly, the present study showed that a higher level of
NT-proBNP was correlated with higher AF burden, a conclusion
based on continuous Holter monitoring. This tendency was
also reflected in the distribution of NT-proBNP levels between
the groups, with higher levels in individuals with a previous
medical history of AF compared with individuals with hAF,
as shown in Figure 1B. In fact, some studies have suggested
that AF burden is related to higher stroke risk (34), and other
biomarker-based models have confirmed NT-proBNP as a stroke
risk surrogate (35).
Although the present study was performed in asymptomatic
patients, NT-proBNP might also be useful for detecting
cryptogenic stroke patients with occult AF. Recently, the negative
results from clinical trials of embolic strokes of undetermined
source (ESUS) patients receiving non-vitamin K antagonists
(NOACs) (36, 37) indicate that this is a heterogeneous group
of patients who need different management, only a minority of
whom have undetected paroxysmal AF (38). In fact, the ongoing
ARCADIA trial (39) will test the use of anticoagulants in ESUS
patients with atrial cardiopathy using high NT-proBNP (>250
pg/ml) as one of the inclusion criteria.
Our study has some limitations. First, the participant selection
was not randomized and might have suffered some selection
bias: the high rates of AF might not be attributed only to
the selection of high-risk patients and long-term monitoring
but also to patients with more cardiac comorbidities being
more prone to participate. The small sample size and the
small number of patients with AF suggest that these results
should be interpreted as hypothesis-generating. The protocol
of the study did not include an echocardiography, missing the
opportunity to establish correlations between biomarkers and
left atrial diameter. Finally, the included population presented
specific risk factors, and the results may not be directly applicable
to populations with other combinations of risk factors. Further
validation studies in larger cohorts are needed.
CONCLUSIONS
NT-proBNP was found to be elevated in AF individuals
compared to controls. This biomarker also detected cases of AF
not previously known or detected by ECG. NT-proBNP may
be useful as a screening biomarker in asymptomatic high-risk
populations with a promising cut-off point of 95 pg/ml that
requires further validation. A screening strategy based on NT-
proBNP, alone or in combination with other biomarkers, might
be of interest for the early initiation of anticoagulants, which
could reduce cardioembolic stroke consequences.
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